Biotech Values

[biomaven0]

>XNPT

Not much new. Horizant sales continue to be minimal. At Cowan they commented that GSK changed its sales system shortly after the drug was approved. Salespeople no longer get incented based on scripts - instead it is based on a formula that includes doctor satisfaction and the like. They sounded enthusiastic about prospects for the drug in Japan though, but it takes some months for pricing etc. to be approved.

BG-12 prodrug on course for Q2 IND. Sounds like they would likely partner after a Phase I. They view psoriasis as a good opportunity too - Biogen can't pursue this because they have no use patent. Arbaclofen results by end of year - this is a good-sized opportunity I think.

Peter